Content about Acquisition

August 28, 2012

Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.

GREENSBORO, N.C. — Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.

August 24, 2012

As several suitors eye individual parts of the Supervalu business, Bloomberg reported that Supervalu is seeking buyers to bid for the entire business.

MINNEAPOLIS — As several suitors eye individual parts of the Supervalu business, Bloomberg reported that Supervalu is seeking buyers to bid for the entire business.

The news sparked a rise in Supervalu shares on Friday. As of press time, shares of Supervalu were up more than 9% to $2.32.

August 10, 2012

BioScrip on Wednesday posted $155.9 million in second-quarter revenue, up 18.5% compared with the prior year.

ELMSFORD, N.Y. — BioScrip on Wednesday posted $155.9 million in second-quarter revenue, up 18.5% compared with the prior year.

"The second-quarter results demonstrate our progress in executing on our strategic plan," BioScrip president and CEO Rick Smith said. "We were able to close on the divestiture of the noncore pharmacy services assets and redeploy a portion of the proceeds towards the acquisition of InfuScience, while delivering sequential improvement on our adjusted EBITDA."

August 8, 2012

Bristol-Myers Squibb has bought a majority stake in drug maker Amylin Pharmaceuticals, Bristol said Wednesday.

NEW YORK — Bristol-Myers Squibb has bought a majority stake in drug maker Amylin Pharmaceuticals, Bristol said Wednesday.

The New York-based drug maker said that 140.5 million shares of Amylin had been put up for sale at $31 per share, and that it now owned 85.55% of the San Diego-based company. Bristol said it planned to acquire the rest of Amylin's shares Wednesday as well.

August 1, 2012

Beiersdorf’s Nivea brand has announced the launch of its first-ever Nivea "Kiss of Style" design contest, which will give one winner the opportunity to design a limited-edition cap for Nivea Lip Care that will be sold in stores.

NEW YORK — Beiersdorf’s Nivea brand has announced the launch of its first-ever Nivea "Kiss of Style" design contest, which will give one winner the opportunity to design a limited-edition cap for Nivea Lip Care that will be sold in stores.

August 1, 2012

Campbell's confirmed that a new leader will take over the company's Pepperidge Farm business.

CAMDEN, N.J. — Campbell's confirmed that a new leader will take over the company's Pepperidge Farm business.

Irene Chang Britt, who has worked at Campbell's since 2005, will replace Pat Callaghan as president of Pepperidge Farm. Britt is the first woman to lead Pepperidge Farm since company founder Margaret Rudkin presided over the business from 1937 to 1966. Pepperidge Farm was acquired by Campbell's in 1961.

Britt will be based at Pepperidge Farm's headquarters in Norwalk, Conn., and will report to Campbell's president and CEO Denise Morrison.

July 31, 2012

An Ahold USA executive has received honors from a New England business publication.

CARLISLE, Pa. — An Ahold USA executive has received honors from a New England business publication.

Ahold USA announced Tuesday that EVP and CFO Paula Price was named 2012 CFO of the Year in the public company category by the Boston Business Journal and was honored at the newspaper's annual luncheon last Wednesday. Ahold USA, a subsidiary of Netherlands-based Royal Ahold, operates the Stop & Shop, Giant-Landover and Giant-Carlisle supermarket chains and the Peapod online grocery service.

July 27, 2012

McLane has entered into an agreement to acquire Meadowbrook Meat Co.

TEMPLE, Texas — McLane has entered into an agreement to acquire Meadowbrook Meat Co.

McLane said MBM — which is one of the nation's largest customized foodservice distributors for national restaurant chains — will continue to be led by the current executive management team and operating out of its existing facilities in the same markets. McLane's acquisition is subject to customary closing conditions, including the termination of the applicable waiting period under the Hart-Scott-Rodino Act.

July 20, 2012

A division of Nestle has bought a stake in a Colorado-based drug maker focused on treatments for neurodegenerative diseases.

BROOMFIELD, Colo. — A division of Nestle has bought a stake in a Colorado-based drug maker focused on treatments for neurodegenerative diseases.

July 11, 2012

Land O'Lakes announced it has agreed to acquire Kozy Shack.

ARDEN HILLS, Minn. — Land O'Lakes announced it has agreed to acquire Kozy Shack.

Kozy Shack, based in New York and founded by Vincent Gruppuso more than 40 years ago, is a "strong strategic fit" for Land O'Lakes and "opens the door for Land O'Lakes to achieve future growth in the attractive dairy dessert category," Land O'Lakes president and CEO Chris Policinski said.

Terms of the acquisition were not disclosed. The transaction is subject to customary closing conditions. The deal is expected to close on July 31.

July 9, 2012

Jel Sert has acquired three functional beverage brand names from Solis Brands.

WEST CHICAGO, Ill. — Jel Sert has acquired three functional beverage brand names from Solis Brands.

July 9, 2012

Narrow networks. They're all the rage.

WHAT IT MEANS AND WHY IT'S IMPORTANT — Narrow networks. They're all the rage. If nothing else, narrow pharmacy benefit management networks emphasize local; and one analysis thread common among all the pundits discussing Walgreens' recent acquisition of USA Drug is that Walgreens just got a whole lot more local across the Southeast.

July 2, 2012

Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

NEW YORK — Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

Bristol announced that it would acquire Amylin for $5.3 billion, or $31 per share. The total value of the acquisition is about $7 billion, including $1.7 billion in Amylin's contractual payment and debt obligations.

June 21, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention.

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.


June 18, 2012

The Federal Trade Commission has approved Giant Food Stores' proposal to acquire 15 Genuardi's stores from Safeway.

CARLISLE, Pa. — The Federal Trade Commission has approved Giant Food Stores' proposal to acquire 15 Genuardi's stores from Safeway.

The announcement follows Giant's Jan. 5 announcement that it would acquire the Genuardi's stores, all of which are located in the greater Philadelphia market. Giant also noted that under the terms of a consent order approved by the FTC, the Genuardi's located in Newtown, Pa., will be purchased by Newtown Market and will be operated as a McCaffrey's supermarket.

June 13, 2012

Upsher-Smith Labs on Wednesday announced that it has agreed to acquire Proximagen Group, a European biotechnology company focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation.

MAPLE GROVE, Minn. — Upsher-Smith Labs on Wednesday announced that it has agreed to acquire Proximagen Group, a European biotechnology company focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation.

Upsher-Smith intends to retain operations in Cambridge and London, England, the company reported.

June 4, 2012

Hi-Tech Pharmacal has acquired rights to a topical drug for treating dermatoses of the scalp from Watson, Hi-Tech said Monday.

AMITYVILLE, N.Y. — Hi-Tech Pharmacal has acquired rights to a topical drug for treating dermatoses of the scalp from Watson, Hi-Tech said Monday.

Hi-Tech announced the acquisition of Cormax (clobetasol propionate) topical solution for an undisclosed sum. The drug had sales of about $600,000 in 2011, according to IMS Health. The drug maker acquired the drug through its ECR Pharmaceuticals subsidiary and plans to launch it this month.

June 4, 2012

Drug maker Takeda Pharmaceutical has finished its purchase of URL Pharma, the companies said Monday.

DEERFIELD, Ill. — Drug maker Takeda Pharmaceutical has finished its purchase of URL Pharma, the companies said Monday.

Japan-based Takeda announced in April that it would buy URL for $800 million. The acquisition, through local subsidiary Takeda Pharmaceuticals USA, gives Takeda control of the gout drug Colcrys (colchicine). URL will report to Takeda Pharmaceuticals USA president Douglas Cole, and the acquisition is expected to boost 2012 sales by $550 million, Takeda said.

May 15, 2012

GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

LONDON — GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

The British drug maker announced that it would buy the shares of Cellzome it doesn't already own for $99 million. Cellzome has labs in the United Kingdom and Germany, and will become part of GSK's research and development organization. The company, of which GSK currently owns 19.98%, develops technologies for profiling compounds in cells and patient samples.

May 15, 2012

Majestic Drug, a manufacturer of niche oral care and personal care products, has named David Fishman as VP.


SOUTH FALLSBURG, N.Y. — Majestic Drug, a manufacturer of niche oral care and personal care products, has named David Fishman as VP.


"We are very proud of our heritage of family involvement in Majestic for over 50 years" Majestic Drug president Larry Fishman said. "My father, Sam Fishman, bought the company in 1960 and brought me on as plant manager in 1970."

May 7, 2012

Walgreens on Monday announced it has completed its acquisition of certain assets of BioScrip’s community specialty pharmacies and centralized specialty and mail-service pharmacy businesses.

DEERFIELD, Ill. — Walgreens on Monday announced it has completed its acquisition of certain assets of BioScrip’s community specialty pharmacies and centralized specialty and mail-service pharmacy businesses. The transaction represents a total deal value of approximately $225 million.

April 26, 2012

Recent events, which have driven Wall Street analysts to speculate that Safeway is a buyout target, are not interrelated, Safeway chairman and CEO Steve Burd assured analysts Thursday morning during the grocer's first-quarter conference call.

PLEASANTON, Calif. — Recent events, which have driven Wall Street analysts to speculate that Safeway is a buyout target, are not interrelated, Safeway chairman and CEO Steve Burd assured analysts Thursday morning during the grocer's first-quarter conference call.

April 26, 2012

Watson has announced its intention to acquire Actavis, the company said.

PARSIPPANY, N.J. — Watson has announced its intention to acquire Actavis, the company said.

Following news reports Tuesday that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced Wednesday that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion.

April 24, 2012

Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

NEW YORK — Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

April 23, 2012

Anglo-Swedish drug maker AstraZeneca will buy a San Diego-based biotech company for $1.26 billion, the two said Monday.

SAN DIEGO — Anglo-Swedish drug maker AstraZeneca will buy a San Diego-based biotech company for $1.26 billion, the two said Monday.